Jak2 (Janus kinase 2) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: Jak2 (Janus kinase 2) Rattus norvegicus
Analyze
Symbol: Jak2
Name: Janus kinase 2
RGD ID: 2939
Description: Enables several functions, including insulin receptor substrate binding activity; phosphatidylinositol 3-kinase binding activity; and signaling receptor binding activity. Involved in several processes, including cell surface receptor signaling pathway; positive regulation of protein transport; and regulation of apoptotic process. Part of euchromatin. Is active in glutamatergic synapse and postsynapse. Used to study several diseases, including hyperuricemia; liver disease (multiple); retinal detachment; thrombocytosis; and transient cerebral ischemia. Biomarker of atherosclerosis; gastrointestinal system cancer (multiple); heart disease; liver cirrhosis; and obesity. Human ortholog(s) of this gene implicated in several diseases, including gastrointestinal system cancer (multiple); hematologic cancer (multiple); hepatic vascular disease (multiple); inflammatory bowel disease (multiple); and lung non-small cell carcinoma (multiple). Orthologous to human JAK2 (Janus kinase 2); PARTICIPATES IN aldosterone signaling pathway; angiotensin II signaling pathway; angiotensin II signaling pathway via AT1 receptor; INTERACTS WITH (4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid; (S)-colchicine; (S)-nicotine.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: JAK-2; Janus kinase 2 (a protein tyrosine kinase); tyrosine-protein kinase JAK2
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81236,408,905 - 236,468,769 (+)NCBIGRCr8
mRatBN7.21226,995,334 - 227,054,381 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1226,995,334 - 227,054,189 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1235,396,988 - 235,455,863 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01242,326,646 - 242,385,527 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01235,144,413 - 235,203,184 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01247,398,667 - 247,457,521 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1247,398,598 - 247,458,509 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01254,646,160 - 254,706,478 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41232,915,995 - 232,974,763 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11233,080,017 - 233,138,786 (+)NCBI
Celera1224,147,256 - 224,206,104 (+)NCBICelera
Cytogenetic Map1q52NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute kidney failure  (ISO)
Acute Lymphoblastic Leukemia, with Lymphomatous Features  (ISO)
acute myeloid leukemia  (ISO)
adrenocortical carcinoma  (ISO)
alcoholic liver cirrhosis  (ISO)
Alzheimer's disease  (ISO)
anemia  (ISO)
ankylosing spondylitis  (ISO)
atherosclerosis  (IEP)
bacterial gastritis  (ISO)
Brain Injuries  (IMP)
Budd-Chiari syndrome  (ISO)
Cachexia  (ISO)
calcinosis  (ISO)
Cancer Pain  (IEP)
chromosome 9p deletion syndrome  (ISO)
chronic myelogenous leukemia, BCR-ABL1 positive  (ISO)
chronic myeloid leukemia  (ISO)
colon adenocarcinoma  (ISO)
colon cancer  (IEP)
colorectal carcinoma  (IEP)
COVID-19  (ISO)
Crohn's disease  (ISO)
Diabetic Nephropathies  (IDA)
esophageal carcinoma  (ISO)
esophagus squamous cell carcinoma  (ISO)
essential thrombocythemia  (ISO,ISS)
Experimental Arthritis  (IDA,ISO)
Experimental Autoimmune Encephalomyelitis  (ISO)
Experimental Colitis  (IEP)
Experimental Liver Cirrhosis  (IEP,ISO)
Experimental Liver Neoplasms  (ISO)
familial erythrocytosis 1  (ISO)
familial erythrocytosis 2  (ISO)
genetic disease  (ISO)
Genetic Predisposition to Disease  (ISO)
glucose intolerance  (ISO)
Growth Disorders  (IEP)
heart disease  (IEP)
heart valve disease  (ISO)
hepatocellular carcinoma  (IEP,ISO)
hereditary breast ovarian cancer syndrome  (ISO)
Hyperalgesia  (IMP,ISO)
hyperuricemia  (IDA)
Inflammation  (ISO)
Intestinal Reperfusion Injury  (IMP)
leukemia  (ISO)
limited scleroderma  (ISO)
liver cancer  (IEP,IMP)
liver cirrhosis  (IEP)
Liver Injury  (IDA)
Liver Reperfusion Injury  (IDA)
lung adenocarcinoma  (ISO)
lung carcinoma  (ISO)
lung non-small cell carcinoma  (ISO)
mesenteric vascular occlusion  (ISO)
metabolic dysfunction-associated steatohepatitis  (ISO)
metabolic dysfunction-associated steatotic liver disease  (IDA,ISO)
myelofibrosis  (ISO,ISS)
myeloid neoplasm  (ISO)
myeloproliferative neoplasm  (ISS)
myocardial infarction  (IMP)
Myocardial Ischemia  (ISO)
Myocardial Reperfusion Injury  (IMP)
nasopharynx carcinoma  (ISO)
Neoplasm Metastasis  (ISO)
Neoplastic Cell Transformation  (ISO)
nephrotic syndrome  (ISO)
Niemann-Pick disease type C1  (ISO)
obesity  (IEP,ISO)
polycythemia  (ISO)
polycythemia vera  (ISO,ISS)
portal hypertension  (IMP)
Pregnancy Complications  (ISO)
primary biliary cholangitis  (IMP)
primary ovarian insufficiency  (ISO)
Prostatic Neoplasms  (ISO)
Reperfusion Injury  (ISO)
retinal detachment  (IDA)
rheumatoid arthritis  (ISO)
scrapie  (ISO)
Sepsis  (IDA)
Sepsis-Associated Encephalopathy  (IDA)
Spinal Cord Injuries  (IMP)
Splenomegaly  (ISO)
Spontaneous Abortions  (ISO)
steatotic liver disease  (ISO)
stomach cancer  (ISO)
Stroke  (IMP)
systemic lupus erythematosus  (ISO)
Thrombocythemia 3  (ISO)
thrombocytosis  (IAGP,ISO)
Thromboembolism  (ISO)
thrombosis  (IAGP)
transient cerebral ischemia  (IDA)
ulcerative colitis  (ISO)
urinary bladder cancer  (ISO)
Uterine Cervical Neoplasms  (ISO)
Venous Thrombosis  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-Arctigenin  (ISO)
(-)-epigallocatechin 3-gallate  (ISO)
(4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid  (EXP)
(S)-colchicine  (EXP)
(S)-nicotine  (EXP,ISO)
1,2-dimethylhydrazine  (ISO)
1-naphthyl isothiocyanate  (EXP)
15-deoxy-Delta(12,14)-prostaglandin J2  (ISO)
17beta-estradiol  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-trinitrobenzenesulfonic acid  (EXP)
2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine  (EXP)
2-amino-2-deoxy-D-glucopyranose  (EXP,ISO)
2-ethoxyethanol  (EXP)
2-hydroxypropanoic acid  (ISO)
2-methoxyethanol  (EXP)
2-palmitoylglycerol  (ISO)
3,4-methylenedioxymethamphetamine  (ISO)
3-chloropropane-1,2-diol  (EXP)
3-methyladenine  (ISO)
3-methylcholanthrene  (ISO)
3-nitropropanoic acid  (EXP)
3-phenylprop-2-enal  (EXP)
3H-1,2-dithiole-3-thione  (EXP)
4,4'-diaminodiphenylmethane  (EXP)
4-hydroxynon-2-enal  (ISO)
5-aza-2'-deoxycytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
7,8-dihydroxycoumarin  (ISO)
7,9-dihydro-1H-purine-2,6,8(3H)-trione  (EXP)
abamectin  (EXP)
acetamide  (EXP)
acetic acid  (EXP)
acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester  (ISO)
actinomycin D  (EXP)
afimoxifene  (ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucosamine  (EXP,ISO)
aldehydo-D-glucose  (EXP,ISO)
aldosterone  (EXP)
all-trans-retinoic acid  (ISO)
all-trans-retinol  (EXP)
aluminium hydroxide  (ISO)
amitrole  (EXP)
amlodipine  (ISO)
ammonium chloride  (EXP)
angiotensin II  (ISO)
antirheumatic drug  (ISO)
apocynin  (ISO)
arecoline  (EXP)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
auranofin  (ISO)
baicalin  (ISO)
Bardoxolone methyl  (ISO)
baricitinib  (ISO)
benzo[a]pyrene  (ISO)
beta-D-glucosamine  (EXP,ISO)
beta-Elemonic acid  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
butyric acid  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
calciol  (ISO)
calcium atom  (ISO)
calcium(0)  (ISO)
cannabidiol  (ISO)
capillarisin  (ISO)
carbon nanotube  (ISO)
ceruletide  (ISO)
chelerythrine  (EXP)
chloroquine  (ISO)
chlorpyrifos  (ISO)
Cirsimarin  (ISO)
cisplatin  (ISO)
clomiphene  (ISO)
clothianidin  (ISO)
clozapine  (EXP)
cocaine  (ISO)
coniferyl aldehyde  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
cordycepin  (ISO)
corticosterone  (EXP)
coumermycin A1  (ISO)
crocin-1  (ISO)
cucurbitacin I  (ISO)
Cuprizon  (ISO)
curcumin  (ISO)
cyclosporin A  (ISO)
cyhalothrin  (EXP)
cypermethrin  (EXP)
D-glucose  (EXP,ISO)
dapagliflozin  (EXP)
daunorubicin  (ISO)
decabromodiphenyl ether  (EXP)
delphinidin  (ISO)
deoxynivalenol  (ISO)
dextran sulfate  (ISO)
diarsenic trioxide  (ISO)
Dibutyl phosphate  (ISO)
dibutyl phthalate  (ISO)
dieldrin  (EXP)
diethylstilbestrol  (ISO)
dimethylarsinic acid  (EXP)
dioxygen  (ISO)
diquat  (ISO)
divanadium pentaoxide  (ISO)
doxorubicin  (ISO)
emodin  (ISO)
eriocitrin  (ISO)
erlotinib hydrochloride  (ISO)
estrone  (ISO)
ethanol  (ISO)
ethyl methanesulfonate  (ISO)
flutamide  (EXP)
folic acid  (ISO)
fraxetin  (ISO)
fructose  (EXP)
fulvestrant  (ISO)
furan  (EXP)
galaxolide  (ISO)
Ganoderic acid A  (ISO)
genistein  (ISO)
Gingerenone A  (ISO)
Ginkgoic acid  (ISO)
glucose  (EXP,ISO)
glutathione  (ISO)
Goe 6976  (EXP,ISO)
gold atom  (ISO)
gold(0)  (ISO)
hesperetin  (EXP)
hesperidin  (EXP)
hexadecanoic acid  (ISO)
hexestrol  (ISO)
hispidulin  (ISO)
hydrogen peroxide  (ISO)
ivermectin  (ISO)
kainic acid  (EXP,ISO)
ketamine  (EXP)
L-arginine  (ISO)
lapatinib  (ISO)
limonin  (ISO)
linagliptin  (EXP,ISO)
lipopolysaccharide  (ISO)
loliolide  (ISO)
losartan  (ISO)
LY294002  (ISO)
melittin  (ISO)
melphalan  (ISO)
mercury atom  (ISO)
mercury dichloride  (ISO)
mercury(0)  (ISO)
mesalamine  (EXP)
mestranol  (ISO)
methimazole  (EXP)
methyl methanesulfonate  (ISO)
methyllycaconitine  (EXP)
methylmercury chloride  (ISO)
Methylthiouracil  (ISO)
mevalonic acid  (EXP)
microcystin-LR  (ISO)
mitoxantrone  (ISO)
Monobutylphthalate  (ISO)
N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide  (EXP)
N-acetyl-L-cysteine  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
nickel atom  (ISO)
nickel dichloride  (EXP)
nicotine  (EXP,ISO)
nimesulide  (ISO)
nitric oxide  (ISO)
Nonylphenol  (ISO)
okadaic acid  (ISO)
olanzapine  (EXP)
oleic acid  (ISO)
ozone  (ISO)
pantoprazole  (ISO)
paracetamol  (ISO)
paroxetine  (ISO)
PD123319  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
phenylpropanolamine  (EXP)
PhIP  (ISO)
phosphane  (EXP)
phosphatidic acid  (ISO)
pipoxolan  (ISO)
pirinixic acid  (ISO)
platycodin D  (ISO)
PNU-282987  (ISO)
ponatinib  (ISO)
Ponicidin  (ISO)
potassium chromate  (ISO)
potassium dichromate  (ISO)
PRIM-O-GLUCOSYLCIMIFUGIN  (ISO)
progesterone  (ISO)
propofol  (ISO)
pterostilbene  (ISO)
quercetin  (EXP,ISO)
quercetin 3-O-beta-D-glucofuranoside  (ISO)
quercetin 3-O-beta-D-glucopyranoside  (ISO)
rac-lactic acid  (ISO)
raloxifene  (ISO)
reactive oxygen species  (ISO)
resveratrol  (ISO)
Rhynchophylline  (EXP)
rotenone  (ISO)
rutin  (EXP)
ruxolitinib  (ISO)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (ISO)
S3I-201  (ISO)
Salinomycin  (ISO)
selumetinib  (ISO)
silibinin  (ISO)
silicon dioxide  (ISO)
simvastatin  (EXP)
Sinomenine  (EXP)
sodium arsenite  (ISO)
sphingosine 1-phosphate  (ISO)
spironolactone  (EXP)
stattic  (ISO)
streptozocin  (EXP)
succimer  (ISO)
sulfadimethoxine  (EXP)
sulfasalazine  (ISO)
sulforaphane  (ISO)
sunitinib  (ISO)
T-2 toxin  (ISO)
tacrolimus hydrate  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone enanthate  (EXP)
tetrachloromethane  (ISO)
theobromine  (EXP)
thymoquinone  (ISO)
Tiron  (ISO)
tofacitinib  (ISO)
trichloroethene  (ISO)
trichostatin A  (ISO)
Triptolide  (ISO)
triptonide  (ISO)
troglitazone  (ISO)
tropisetron  (EXP)
tyrphostin B42  (EXP,ISO)
umbelliferone  (EXP)
urethane  (ISO)
valproic acid  (ISO)
valsartan  (ISO)
verteporfin  (ISO)
vinclozolin  (EXP)
zidovudine  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
adaptive immune response  (IEA)
axon regeneration  (IMP)
cell differentiation  (ISO)
cell surface receptor signaling pathway via JAK-STAT  (IBA,IDA,ISO)
cellular response to dexamethasone stimulus  (ISO)
cellular response to interleukin-3  (ISO)
cellular response to lipopolysaccharide  (ISO)
chromatin organization  (IEA)
chromatin remodeling  (IEA)
collagen-activated signaling pathway  (ISO)
cytokine-mediated signaling pathway  (IBA,IEA,ISO,ISS)
enzyme-linked receptor protein signaling pathway  (ISO)
erythrocyte differentiation  (IBA,ISO,ISS)
erythropoietin-mediated signaling pathway  (ISO)
extrinsic apoptotic signaling pathway  (ISO)
G protein-coupled receptor signaling pathway  (IMP)
granulocyte-macrophage colony-stimulating factor signaling pathway  (ISO)
growth hormone receptor signaling pathway  (ISO)
growth hormone receptor signaling pathway via JAK-STAT  (IBA,IDA,ISO,ISS)
hormone-mediated signaling pathway  (IDA)
interleukin-12-mediated signaling pathway  (ISO)
interleukin-23-mediated signaling pathway  (ISO)
interleukin-3-mediated signaling pathway  (ISO)
interleukin-5-mediated signaling pathway  (ISO)
intracellular signal transduction  (IBA,IEA,ISO)
intrinsic apoptotic signaling pathway in response to oxidative stress  (IMP)
mammary gland epithelium development  (ISO)
microglial cell activation  (ISO)
modulation of chemical synaptic transmission  (IDA,IMP)
myeloid cell differentiation  (ISO)
negative regulation of apoptotic process  (IMP,ISO)
negative regulation of cardiac muscle cell apoptotic process  (IMP)
negative regulation of cell population proliferation  (ISO)
negative regulation of cell-cell adhesion  (IMP)
negative regulation of neuron apoptotic process  (IMP)
nuclear receptor-mediated mineralocorticoid signaling pathway  (IMP)
platelet-derived growth factor receptor signaling pathway  (IMP)
positive regulation of apoptotic process  (IMP)
positive regulation of apoptotic signaling pathway  (ISO)
positive regulation of cell activation  (IMP)
positive regulation of cell differentiation  (IMP)
positive regulation of cell migration  (IMP)
positive regulation of cell population proliferation  (IEA,IMP)
positive regulation of cell-substrate adhesion  (ISO)
positive regulation of cold-induced thermogenesis  (ISO,ISS)
positive regulation of cytosolic calcium ion concentration  (IMP)
positive regulation of DNA binding  (IMP)
positive regulation of DNA-binding transcription factor activity  (IMP)
positive regulation of epithelial cell apoptotic process  (IMP)
positive regulation of growth factor dependent skeletal muscle satellite cell proliferation  (IMP)
positive regulation of growth hormone receptor signaling pathway  (ISO)
positive regulation of insulin secretion  (IMP)
positive regulation of interleukin-1 beta production  (IMP,ISO)
positive regulation of leukocyte proliferation  (ISO)
positive regulation of MAPK cascade  (IMP)
positive regulation of MHC class II biosynthetic process  (ISO)
positive regulation of natural killer cell proliferation  (ISO)
positive regulation of nitric oxide biosynthetic process  (IMP)
positive regulation of nitric-oxide synthase biosynthetic process  (IDA,ISO)
positive regulation of NK T cell proliferation  (ISO)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction  (ISO)
positive regulation of phosphoprotein phosphatase activity  (IMP)
positive regulation of platelet activation  (ISO)
positive regulation of platelet aggregation  (ISO)
positive regulation of protein import into nucleus  (IMP)
positive regulation of receptor signaling pathway via JAK-STAT  (ISO)
positive regulation of SMAD protein signal transduction  (ISO)
positive regulation of T cell proliferation  (ISO)
positive regulation of transcription by RNA polymerase II  (ISO)
positive regulation of tumor necrosis factor production  (ISO)
positive regulation of type II interferon production  (ISO)
positive regulation of tyrosine phosphorylation of STAT protein  (ISO,ISS)
positive regulation of vascular associated smooth muscle cell proliferation  (IMP)
post-embryonic hemopoiesis  (ISO)
post-translational protein modification  (ISO,ISS)
protein autophosphorylation  (IMP)
regulation of apoptotic process  (IBA)
regulation of inflammatory response  (ISO)
regulation of nitric oxide biosynthetic process  (IGI)
regulation of postsynapse to nucleus signaling pathway  (EXP,IDA)
response to amine  (IEP)
response to antibiotic  (ISO)
response to hydroperoxide  (IMP)
response to interleukin-12  (ISO)
response to lipopolysaccharide  (ISO)
response to organic cyclic compound  (IEP)
response to oxidative stress  (IMP)
response to tumor necrosis factor  (ISO)
signal transduction  (ISO,ISS)
symbiont-induced defense-related programmed cell death  (ISO)
transcription by RNA polymerase II  (ISO)
tumor necrosis factor-mediated signaling pathway  (ISO)
type II interferon-mediated signaling pathway  (IDA)
tyrosine phosphorylation of STAT protein  (IMP)

References

References - curated
# Reference Title Reference Citation
1. Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK/STAT- and phosphatidylinositol 3-kinase/Rac1/NAPDH oxidase/H2O2-dependent pathways. Alblas J, etal., Mol Cell Biol. 2005 Aug;25(16):7181-92. doi: 10.1128/MCB.25.16.7181-7192.2005.
2. Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. Ali MS, etal., J Biol Chem. 1997 Sep 12;272(37):23382-8.
3. An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. Arena S, etal., Mol Endocrinol. 2007 Jan;21(1):229-46. Epub 2006 Oct 4.
4. Ngn3 expression during postnatal in vitro beta cell neogenesis induced by the JAK/STAT pathway. Baeyens L, etal., Cell Death Differ. 2006 Nov;13(11):1892-9. Epub 2006 Mar 3.
5. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Baxter EJ, etal., Lancet. 2005 Mar 19-25;365(9464):1054-61.
6. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Byun HJ, etal., Oncol Rep. 2017 Jun;37(6):3270-3278. doi: 10.3892/or.2017.5588. Epub 2017 Apr 19.
7. Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population. Chen C, etal., Clin Immunol. 2010 Sep;136(3):442-6. Epub 2010 Jun 2.
8. Sinomenine attenuates cancer-induced bone pain via suppressing microglial JAK2/STAT3 and neuronal CAMKII/CREB cascades in rat models. Chen SP, etal., Mol Pain. 2018 Jan-Dec;14:1744806918793232. doi: 10.1177/1744806918793232. Epub 2018 Jul 20.
9. Clinicopathologic and prognostic significance of VEGF, JAK2 and STAT3 in patients with nasopharyngeal carcinoma. Cheng JZ, etal., Cancer Cell Int. 2018 Aug 13;18:110. doi: 10.1186/s12935-018-0605-0. eCollection 2018.
10. Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Chiba T, etal., Mol Psychiatry. 2009 Feb;14(2):206-22. doi: 10.1038/mp.2008.105. Epub 2008 Sep 23.
11. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. Colaizzo D, etal., J Thromb Haemost. 2007 Jan;5(1):55-61. Epub 2006 Oct 20.
12. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma. Corbit KC, etal., JCI Insight. 2019 Aug 8;5. pii: 131310. doi: 10.1172/jci.insight.131310.
13. JAK/STAT signaling pathway mediates cytokine-induced iNOS expression in primary astroglial cell cultures. Dell'Albani P, etal., J Neurosci Res. 2001 Sep 1;65(5):417-24.
14. JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. Dominguez E, etal., J Neurochem. 2008 Oct;107(1):50-60. Epub 2008 Jul 12.
15. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway. Du W, etal., J Cell Mol Med. 2012 Aug;16(8):1878-88. doi: 10.1111/j.1582-4934.2011.01483.x.
16. SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. Duan C, etal., J Biol Chem. 2004 Oct 15;279(42):43684-91. Epub 2004 Aug 16.
17. Cloning of the gene encoding rat JAK2, a protein tyrosine kinase. Duhe RJ, etal., Gene 1995 Jun 9;158(2):281-5.
18. Involvement of JAK2 upstream of the PI 3-kinase in cell-cell adhesion regulation by gastrin. Ferrand A, etal., Exp Cell Res. 2004 Dec 10;301(2):128-38.
19. Requirement of Ca(2+) and PKCdelta for Janus kinase 2 activation by angiotensin II: involvement of PYK2. Frank GD, etal., Mol Endocrinol 2002 Feb;16(2):367-77.
20. Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Freitas MC, etal., Liver Transpl. 2010 May;16(5):600-10.
21. JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Gao SP, etal., Sci Signal. 2016 Mar 29;9(421):ra33. doi: 10.1126/scisignal.aac8460.
22. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
23. Activation of the Jak/Stat signal transduction pathway in GH-treated rat osteoblast-like cells in culture. Gerland K, etal., Mol Cell Endocrinol. 2000 Oct 25;168(1-2):1-9.
24. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
25. Gene expression profile of omental adipose tissue in human obesity. Gomez-Ambrosi J, etal., FASEB J. 2004 Jan;18(1):215-7. Epub 2003 Nov 20.
26. AG490 prevents cell death after exposure of rat astrocytes to hydrogen peroxide or proinflammatory cytokines: involvement of the Jak2/STAT pathway. Gorina R, etal., J Neurochem. 2005 Feb;92(3):505-18.
27. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Granzow M, etal., Hepatology. 2014 Jul;60(1):334-48. doi: 10.1002/hep.27117. Epub 2014 May 6.
28. Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Guo D, etal., Oncotarget. 2017 Jun 13;8(24):39640-39648. doi: 10.18632/oncotarget.17387.
29. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ha JS, etal., Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.
30. The growth hormone receptor associates with Jak1, Jak2 and Tyk2 in human liver. Hellgren G, etal., Growth Horm IGF Res. 1999 Jun;9(3):212-8.
31. Growth hormone receptor interaction with Jak proteins differs between tissues. Hellgren G, etal., J Interferon Cytokine Res. 2001 Feb;21(2):75-83.
32. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hou J, etal., Hepatology. 2013 Feb;57(2):678-88. doi: 10.1002/hep.25980. Epub 2012 Oct 30.
33. Attenuation of leptin and insulin signaling by SOCS proteins. Howard JK and Flier JS, Trends Endocrinol Metab. 2006 Nov;17(9):365-71. Epub 2006 Sep 28.
34. NVP-BSK805, an Inhibitor of JAK2 Kinase, Significantly Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma in vitro and in vivo. Hua Y, etal., Drug Des Devel Ther. 2020 Feb 24;14:745-755. doi: 10.2147/DDDT.S203048. eCollection 2020.
35. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. James C, etal., Nature. 2005 Apr 28;434(7037):1144-8.
36. Angiotensin II induces angiogenic factors production partly via AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells. Ji Y, etal., Cell Physiol Biochem. 2012;29(5-6):863-74. doi: 10.1159/000171034. Epub 2012 May 11.
37. Amelioration of experimental autoimmune encephalomyelitis by plumbagin through down-regulation of JAK-STAT and NF-kappaB signaling pathways. Jia Y, etal., PLoS One. 2011;6(10):e27006. Epub 2011 Oct 31.
38. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer. Jin J, etal., Pathol Oncol Res. 2019 Apr;25(2):769-775. doi: 10.1007/s12253-019-00592-6. Epub 2019 Jan 31.
39. Reduction of adiposity with prolonged growth hormone treatment in old obese rats: effects on glucose handling and early insulin signaling. Johansen T, etal., Growth Horm IGF Res. 2005 Feb;15(1):55-63. Epub 2005 Jan 22.
40. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Jones SA, etal., J Clin Invest. 2011 Sep 1;121(9):3375-83. doi: 10.1172/JCI57158. Epub 2011 Sep 1.
41. Melatonin inhibits type 1 interferon signaling of toll-like receptor 4 via heme oxygenase-1 induction in hepatic ischemia/reperfusion. Kang JW and Lee SM, J Pineal Res. 2012 Aug;53(1):67-76. doi: 10.1111/j.1600-079X.2012.00972.x. Epub 2012 Jan 31.
42. KEGG: Kyoto Encyclopedia of Genes and Genomes KEGG
43. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. Kirabo A, etal., Am J Pathol. 2012 Sep;181(3):858-65. doi: 10.1016/j.ajpath.2012.05.033. Epub 2012 Jul 13.
44. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Klein S, etal., Gut. 2017 Jan;66(1):145-155. doi: 10.1136/gutjnl-2015-309600. Epub 2015 Sep 17.
45. Lactogens protect rodent and human beta cells against glucolipotoxicity-induced cell death through Janus kinase-2 (JAK2)/signal transducer and activator of transcription-5 (STAT5) signalling. Kondegowda NG, etal., Diabetologia. 2012 Jun;55(6):1721-32. doi: 10.1007/s00125-012-2501-9. Epub 2012 Mar 3.
46. Down-regulation of insulin signaling is involved in painful diabetic neuropathy in type 2 diabetes. Kou ZZ, etal., Pain Physician. 2013 Mar-Apr;16(2):E71-83.
47. A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, etal., N Engl J Med. 2005 Apr 28;352(17):1779-90.
48. Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS. Kurdi M and Booz GW, J Cell Physiol. 2007 Aug;212(2):424-31.
49. Interleukin-6-induced satellite cell proliferation is regulated by induction of the JAK2/STAT3 signalling pathway through cyclin D1 targeting. Kurosaka M and Machida S, Cell Prolif. 2013 Aug;46(4):365-73. doi: 10.1111/cpr.12045.
50. Kinase activity and subcellular distribution of a chimeric green fluorescent protein-tagged Janus kinase 2. Lee S and Duhe RJ, J Biomed Sci. 2006 Nov;13(6):773-86. Epub 2006 Sep 14.
51. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Li R, etal., Am J Nephrol. 2007;27(6):580-9. Epub 2007 Sep 6.
52. Therapeutic effect of 7, 3'-dimethoxy hesperetin on adjuvant arthritis in rats through inhibiting JAK2-STAT3 signal pathway. Li R, etal., Int Immunopharmacol. 2012 Oct;14(2):157-63. doi: 10.1016/j.intimp.2012.07.001. Epub 2012 Jul 15.
53. Effects of propofol on invasion and migration of colon cancer cells and JAK2/STAT3 signaling pathway. Liang B and Dong T, Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Mar 28;45(3):290-296. doi: 10.11817/j.issn.1672-7347.2020.180704.
54. Ginkgolic acid (GA) suppresses gastric cancer growth by inducing apoptosis and suppressing STAT3/JAK2 signaling regulated by ROS. Liang JR and Yang H, Biomed Pharmacother. 2020 May;125:109585. doi: 10.1016/j.biopha.2019.109585. Epub 2020 Feb 25.
55. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. Liang L, etal., J Exp Clin Cancer Res. 2019 Feb 12;38(1):71. doi: 10.1186/s13046-019-1093-3.
56. Ilex paraguariensis (yerba mate) improves endocrine and metabolic disorders in obese rats primed by early weaning. Lima Nda S, etal., Eur J Nutr. 2014 Feb;53(1):73-82. doi: 10.1007/s00394-013-0500-3. Epub 2013 Feb 9.
57. Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway. Liu JR, etal., Pathol Res Pract. 2015 Jun;211(6):426-34. doi: 10.1016/j.prp.2015.01.007. Epub 2015 Jan 24.
58. Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer. Liu K, etal., Cancer Sci. 2018 May;109(5):1369-1381. doi: 10.1111/cas.13575. Epub 2018 Apr 17.
59. Ponicidin induces apoptosis via JAK2 and STAT3 signaling pathways in gastric carcinoma. Liu YF, etal., Int J Mol Sci. 2015 Jan 12;16(1):1576-89. doi: 10.3390/ijms16011576.
60. Constitutive nuclear localization of Janus kinases 1 and 2. Lobie PE, etal., Endocrinology. 1996 Sep;137(9):4037-45.
61. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. Lu LD, etal., J Immunol. 2011 Oct 1;187(7):3840-53. Epub 2011 Aug 31.
62. SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates. Maegawa H, etal., Biochem Biophys Res Commun. 1996 Nov 1;228(1):122-7.
63. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Marty C, etal., Blood. 2014 Feb 27;123(9):1372-83. doi: 10.1182/blood-2013-05-504555. Epub 2014 Jan 7.
64. Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells. Masamune A, etal., World J Gastroenterol. 2005 Jun 14;11(22):3385-91.
65. Janus kinase-2 signaling mediates apoptosis in rat cardiomyocytes. Mascareno E, etal., Vascul Pharmacol. 2005 Nov;43(5):327-35. Epub 2005 Nov 2.
66. An inhibitor of Janus kinase 2 prevents polycythemia in mice. Mathur A, etal., Biochem Pharmacol. 2009 Aug 15;78(4):382-9. doi: 10.1016/j.bcp.2009.04.025. Epub 2009 May 3.
67. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
68. miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2-STAT3 signaling. Miao L, etal., Cancer Immunol Immunother. 2014 Jul;63(7):699-711. doi: 10.1007/s00262-014-1550-y. Epub 2014 Apr 10.
69. 1Alpha,25-dihydroxyvitamin D3 inhibits GH-induced expression of SOCS-3 and CIS and prolongs growth hormone signaling via the Janus kinase (JAK2)/signal transducers and activators of transcription (STAT5) system in osteoblast-like cells. Morales O, etal., J Biol Chem 2002 Sep 20;277(38):34879-84.
70. The JAK-STAT signaling pathway: input and output integration. Murray PJ J Immunol. 2007 Mar 1;178(5):2623-9.
71. JAK-STAT signaling pathway mediates astrogliosis in brains of scrapie-infected mice. Na YJ, etal., J Neurochem. 2007 Oct;103(2):637-49.
72. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
73. An essential role of the Jak-2/STAT-3/cytosolic phospholipase A(2) axis in platelet-derived growth factor BB-induced vascular smooth muscle cell motility. Neeli I, etal., J Biol Chem. 2004 Oct 29;279(44):46122-8. Epub 2004 Aug 22.
74. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Neubauer H, etal., Cell 1998 May 1;93(3):397-409.
75. The Jak/STAT pathway is involved in synaptic plasticity. Nicolas CS, etal., Neuron. 2012 Jan 26;73(2):374-90. doi: 10.1016/j.neuron.2011.11.024.
76. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
77. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart. Pan J, etal., Circ Res. 1997 Oct;81(4):611-7.
78. Jak2 is essential for signaling through a variety of cytokine receptors. Parganas E, etal., Cell 1998 May 1;93(3):385-95.
79. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. Park EJ, etal., J Biol Chem 2003 Apr 25;278(17):14747-52. Epub 2003 Feb 12.
80. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Peeters P, etal., Blood. 1997 Oct 1;90(7):2535-40.
81. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. Pendergrass SA, etal., PLoS One. 2010 Aug 17;5(8):e12106.
82. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
83. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
84. Investigation of JAK2, STAT3 and CCR6 polymorphisms and their gene-gene interactions in inflammatory bowel disease. Polgar N, etal., Int J Immunogenet. 2012 Jan 23. doi: 10.1111/j.1744-313X.2012.01084.x.
85. Conditioning injury-induced spinal axon regeneration requires signal transducer and activator of transcription 3 activation. Qiu J, etal., J Neurosci. 2005 Feb 16;25(7):1645-53.
86. Novel 1,4-benzothazines obliterate COX-2 mediated JAK-2/STAT-3 signals with potential regulation of oxidative and metabolic stress during colorectal cancer. Rai A, etal., Pharmacol Res. 2018 Jun;132:188-203. doi: 10.1016/j.phrs.2017.12.010. Epub 2017 Dec 8.
87. JAKs, STATs and Src kinases in hematopoiesis. Rane SG and Reddy EP, Oncogene 2002 May 13;21(21):3334-58.
88. 5,7,3'-Triacetyl hesperetin suppresses adjuvant-induced arthritis in rats through modulating JAK2/STAT3 pathway. Ren DY, etal., Am J Chin Med. 2013;41(3):601-14. doi: 10.1142/S0192415X13500420.
89. Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway. Ren S, etal., Int J Biochem Cell Biol. 2020 Aug;125:105777. doi: 10.1016/j.biocel.2020.105777. Epub 2020 Jun 3.
90. GOA pipeline RGD automated data pipeline
91. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
92. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
93. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Russell RC, etal., Nat Med. 2011 Jun 19;17(7):845-53. doi: 10.1038/nm.2370.
94. Human umbilical cord blood-derived mesenchymal stem cells protect against neuronal cell death and ameliorate motor deficits in Niemann Pick type C1 mice. Seo Y, etal., Cell Transplant. 2011;20(7):1033-47. doi: 10.3727/096368910X545086. Epub 2010 Dec 22.
95. Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. Shaw S, etal., J Biol Chem 2002 Nov 22;277(47):44920-4.
96. JAK2 promotes brown adipose tissue function and is required for diet- and cold-induced thermogenesis in mice. Shi SY, etal., Diabetologia. 2016 Jan;59(1):187-96. doi: 10.1007/s00125-015-3786-2. Epub 2015 Oct 29.
97. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. Shi SY, etal., J Biol Chem. 2012 Mar 23;287(13):10277-88. Epub 2012 Jan 24.
98. Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice. Shi SY, etal., J Biol Chem. 2017 Mar 3;292(9):3789-3799. doi: 10.1074/jbc.M116.752519. Epub 2017 Jan 18.
99. Oncopreventive effects of theanine and theobromine on dimethylhydrazine-induced colon cancer model. Shojaei-Zarghani S, etal., Biomed Pharmacother. 2021 Feb;134:111140. doi: 10.1016/j.biopha.2020.111140. Epub 2020 Dec 24.
100. Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. Shyu WC, etal., J Clin Invest. 2008 Jan;118(1):133-48.
101. Novel fused oxazepino-indoles (FOIs) attenuate liver carcinogenesis via IL-6/JAK2/STAT3 signaling blockade as evidenced through data-based mathematical modeling. Singh AK, etal., Life Sci. 2018 May 15;201:161-172. doi: 10.1016/j.lfs.2018.02.029. Epub 2018 Feb 24.
102. Protective effect of ginkgolide B against acute spinal cord injury in rats and its correlation with the Jak/STAT signaling pathway. Song Y, etal., Neurochem Res. 2013 Mar;38(3):610-9. doi: 10.1007/s11064-012-0959-y. Epub 2012 Dec 29.
103. High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis. Sonohara F, etal., Oncol Rep. 2015 Feb;33(2):767-73. doi: 10.3892/or.2014.3621. Epub 2014 Nov 25.
104. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Stump KL, etal., Arthritis Res Ther. 2011 Apr 21;13(2):R68.
105. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Sugiyama T, etal., Endocrinology. 2005 Sep;146(9):3900-6. Epub 2005 Jun 2.
106. Apigetrin inhibits gastric cancer progression through inducing apoptosis and regulating ROS-modulated STAT3/JAK2 pathway. Sun Q, etal., Biochem Biophys Res Commun. 2018 Mar 25;498(1):164-170. doi: 10.1016/j.bbrc.2018.02.009. Epub 2018 Mar 5.
107. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. Sun Y, etal., J Thorac Oncol. 2011 Apr;6(4):699-706. doi: 10.1097/JTO.0b013e31820d9d11.
108. Opposite effect of JAK2 on insulin-dependent activation of mitogen-activated protein kinases and Akt in muscle cells: possible target to ameliorate insulin resistance. Thirone AC, etal., Diabetes. 2006 Apr;55(4):942-51.
109. Epiphyseal growth plate growth hormone receptor signaling is decreased in chronic kidney disease-related growth retardation. Troib A, etal., Kidney Int. 2013 Nov;84(5):940-9. doi: 10.1038/ki.2013.196. Epub 2013 May 29.
110. Sequential activation of JAKs, STATs and xanthine dehydrogenase/oxidase by hypoxia in lung microvascular endothelial cells. Wang G, etal., Int J Biochem Cell Biol. 2008;40(3):461-70. Epub 2007 Aug 30.
111. Total glucosides of paeony regulates JAK2/STAT3 activation and macrophage proliferation in diabetic rat kidneys. Wang K, etal., Am J Chin Med. 2012;40(3):521-36.
112. N-Acetylcysteine and allopurinol up-regulated the Jak/STAT3 and PI3K/Akt pathways via adiponectin and attenuated myocardial postischemic injury in diabetes. Wang T, etal., Free Radic Biol Med. 2013 Oct;63:291-303. doi: 10.1016/j.freeradbiomed.2013.05.043. Epub 2013 Jun 6.
113. [Effect of oxymatrine on JAK2/STAT3 signaling in renal tissues of rats with septic shock]. Wang XY, etal., Zhongguo Zhong Yao Za Zhi. 2013 Aug;38(16):2696-700.
114. Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells. Watanabe S, etal., Am J Nephrol. 2004 Jul-Aug;24(4):387-92. Epub 2004 Jul 9.
115. Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways. Wazea SA, etal., Sci Rep. 2018 Mar 23;8(1):5110. doi: 10.1038/s41598-018-23359-6.
116. Ischemic postconditioning during reperfusion attenuates intestinal injury and mucosal cell apoptosis by inhibiting JAK/STAT signaling activation. Wen SH, etal., Shock. 2012 Oct;38(4):411-9. doi: 10.1097/SHK.0b013e3182662266.
117. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Westbrook RH, etal., Liver Transpl. 2012 Jul;18(7):819-27. doi: 10.1002/lt.23443.
118. Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18. 3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis. William AD, etal., J Med Chem. 2012 Mar 22;55(6):2623-40. doi: 10.1021/jm201454n. Epub 2012 Mar 6.
119. Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Wold LE, etal., Hypertension 2002 Jan;39(1):69-74.
120. Da-Huang-Fu-Zi-Tang attenuates liver injury in rats with severe acute pancreatitis. Wu L, etal., J Ethnopharmacol. 2013 Dec 12;150(3):960-6. doi: 10.1016/j.jep.2013.09.051. Epub 2013 Oct 24.
121. Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway. Wu L, etal., Oncol Rep. 2015 Dec;34(6):3311-7. doi: 10.3892/or.2015.4279. Epub 2015 Sep 16.
122. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Wu X, etal., Oncotarget. 2017 Mar 28;8(13):20741-20750. doi: 10.18632/oncotarget.15119.
123. Effects of supplemental erythropoietin on its receptor expression and signal transduction pathways in rat model of retinal detachment. Xie Z, etal., Curr Eye Res. 2012 Feb;37(2):138-44. doi: 10.3109/02713683.2011.647225.
124. The effect of JAK2 knockout on inhibition of liver tumor growth by inducing apoptosis, autophagy and anti-proliferation via STATs and PI3K/AKT signaling pathways. Xu Y and Lv SX, Biomed Pharmacother. 2016 Dec;84:1202-1212. doi: 10.1016/j.biopha.2016.09.040. Epub 2016 Oct 24.
125. Emulsified isoflurane induces postconditioning against myocardial infarction via JAK-STAT pathway. Yan L, etal., J Surg Res. 2012 Dec;178(2):578-85. doi: 10.1016/j.jss.2012.06.007. Epub 2012 Jun 21.
126. Janus kinase 2 polymorphisms are associated with risk in patients with gastric cancer in a Chinese population. Yang L, etal., PLoS One. 2013 May 24;8(5):e64628. doi: 10.1371/journal.pone.0064628. Print 2013.
127. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. Yang Y, etal., J Pineal Res. 2013 Oct;55(3):275-86. doi: 10.1111/jpi.12070. Epub 2013 Jun 25.
128. Prolactin promotes hepatocellular carcinoma through Janus kinase 2. Yeh YT, etal., World J Surg. 2012 May;36(5):1128-35. doi: 10.1007/s00268-012-1505-4.
129. Suppression of IL-1beta expression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells. Yu JH, etal., Biochem Pharmacol. 2006 Nov 30;72(11):1555-62. Epub 2006 Aug 24.
130. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. Yu X, etal., J Biol Chem. 2003 May 2;278(18):16304-9. Epub 2003 Feb 20.
131. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis. Zerjavic K, etal., Thromb Res. 2013 Aug;132(2):e86-93. doi: 10.1016/j.thromres.2013.06.021. Epub 2013 Jul 9.
132. Protection of curcumin against fructose-induced hyperuricaemia and renal endothelial dysfunction involves NO-mediated JAK-STAT signalling in rats. Zhang DM, etal., Food Chem. 2012 Oct 15;134(4):2184-93. doi: 10.1016/j.foodchem.2012.04.026. Epub 2012 Apr 17.
133. Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormone-stimulated increases in cytosolic free Ca2+ and insulin secretion. Zhang F, etal., Am J Physiol Cell Physiol. 2006 Sep;291(3):C466-75. Epub 2006 Apr 5.
134. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Zhang FQ, etal., Oncotarget. 2015 Jun 10;6(16):14329-43. doi: 10.18632/oncotarget.3685.
135. Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer. Zhang L, etal., Inflamm Res. 2019 Sep;68(9):751-760. doi: 10.1007/s00011-019-01258-4. Epub 2019 Jun 26.
136. Oxymatrine protects against myocardial injury via inhibition of JAK2/STAT3 signaling in rat septic shock. Zhang M, etal., Mol Med Rep. 2013 Apr;7(4):1293-9. doi: 10.3892/mmr.2013.1315. Epub 2013 Feb 8.
137. Amyloid-beta induces hepatic insulin resistance in vivo via JAK2. Zhang Y, etal., Diabetes. 2013 Apr;62(4):1159-66. doi: 10.2337/db12-0670. Epub 2012 Dec 6.
138. Suppression of JAK2/STAT3 signaling reduces end-to-end arterial anastomosis induced cell proliferation in common carotid arteries of rats. Zhao J, etal., PLoS One. 2013;8(3):e58730. doi: 10.1371/journal.pone.0058730. Epub 2013 Mar 14.
139. Activation of JAK2/STAT pathway in cerebral cortex after experimental traumatic brain injury of rats. Zhao JB, etal., Neurosci Lett. 2011 Jul 8;498(2):147-52. Epub 2011 May 10.
140. [Effects of puerarin on expressions of leptin receptor mRNA, phosphorylated Janus kinase 2/phosphorylated signal transducers and activators of transcription 3 proteins in the liver of rats with non-alcoholic fatty liver]. Zheng PY, etal., Zhong Xi Yi Jie He Xue Bao. 2008 Sep;6(9):921-7.
141. Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia. Zhou TF and Yu JG, J Surg Res. 2013 Jul;183(1):304-12. doi: 10.1016/j.jss.2012.11.035. Epub 2012 Dec 6.
142. Elevated retinol binding protein 4 levels are associated with atherosclerosis in diabetic rats via JAK2/STAT3 signaling pathway. Zhou W, etal., World J Diabetes. 2021 Apr 15;12(4):466-479. doi: 10.4239/wjd.v12.i4.466.
143. SMND-309, a novel derivative of salvianolic acid B, protects rat brains ischemia and reperfusion injury by targeting the JAK2/STAT3 pathway. Zhu H, etal., Eur J Pharmacol. 2013 Aug 15;714(1-3):23-31. doi: 10.1016/j.ejphar.2013.05.043. Epub 2013 Jun 11.
Additional References at PubMed
PMID:7527668   PMID:7528775   PMID:7538110   PMID:7782332   PMID:7961995   PMID:8022486   PMID:8378315   PMID:8400282   PMID:8609418   PMID:8923468   PMID:9111318   PMID:9727029  
PMID:10600756   PMID:10822380   PMID:10872802   PMID:10925297   PMID:11201744   PMID:11489994   PMID:11493922   PMID:11821424   PMID:12040017   PMID:12147240   PMID:12388746   PMID:12426001  
PMID:12538627   PMID:12777386   PMID:12941779   PMID:12960006   PMID:14522994   PMID:14678947   PMID:15012602   PMID:15065871   PMID:15143187   PMID:15156153   PMID:15159394   PMID:15354294  
PMID:15591245   PMID:15746188   PMID:15958724   PMID:16025117   PMID:16280321   PMID:16297319   PMID:17332060   PMID:17496209   PMID:17519522   PMID:17526654   PMID:17565041   PMID:17607690  
PMID:17726028   PMID:17728251   PMID:17761766   PMID:18006272   PMID:18499741   PMID:18582595   PMID:18611343   PMID:18798867   PMID:19063868   PMID:19276765   PMID:19350281   PMID:19435852  
PMID:19625377   PMID:19665053   PMID:19748527   PMID:19781194   PMID:19783980   PMID:19888448   PMID:20122990   PMID:20304997   PMID:20492356   PMID:20530874   PMID:20724918   PMID:20817061  
PMID:20848345   PMID:20976841   PMID:20979831   PMID:21036157   PMID:21470923   PMID:21502705   PMID:21509626   PMID:21536676   PMID:21606371   PMID:21808064   PMID:21813872   PMID:21841788  
PMID:21929289   PMID:22125600   PMID:22466958   PMID:22561747   PMID:22697788   PMID:22820988   PMID:22948409   PMID:23061660   PMID:23449887   PMID:23544085   PMID:24013029   PMID:24018979  
PMID:24463190   PMID:24965138   PMID:25129435   PMID:25380525   PMID:25500624   PMID:25537973   PMID:25559502   PMID:25731682   PMID:25986861   PMID:26227742   PMID:26261556   PMID:26527061  
PMID:26802935   PMID:26884823   PMID:27003918   PMID:27057278   PMID:27301615   PMID:27337676   PMID:27450794   PMID:27573711   PMID:27717845   PMID:28334068   PMID:28385490   PMID:28782583  
PMID:28782829   PMID:29032602   PMID:29061394   PMID:29174854   PMID:29210652   PMID:29550470   PMID:29580751   PMID:30552029   PMID:31264277   PMID:31406138   PMID:31454541   PMID:31545485  
PMID:31564534   PMID:31703282   PMID:31746349   PMID:31841394   PMID:31982878   PMID:32016456   PMID:32647179   PMID:33522063   PMID:33729996   PMID:34081793   PMID:34516361   PMID:35042436  
PMID:35122774   PMID:36446389   PMID:37232379   PMID:37338759   PMID:37641874   PMID:37759514   PMID:38154546   PMID:38306778   PMID:38796983  


Genomics

Comparative Map Data
Jak2
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81236,408,905 - 236,468,769 (+)NCBIGRCr8
mRatBN7.21226,995,334 - 227,054,381 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1226,995,334 - 227,054,189 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1235,396,988 - 235,455,863 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01242,326,646 - 242,385,527 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01235,144,413 - 235,203,184 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01247,398,667 - 247,457,521 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1247,398,598 - 247,458,509 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01254,646,160 - 254,706,478 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41232,915,995 - 232,974,763 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11233,080,017 - 233,138,786 (+)NCBI
Celera1224,147,256 - 224,206,104 (+)NCBICelera
Cytogenetic Map1q52NCBI
JAK2
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh3894,984,390 - 5,129,948 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl94,984,390 - 5,129,948 (+)EnsemblGRCh38hg38GRCh38
GRCh3794,984,390 - 5,129,948 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 3694,975,245 - 5,117,995 (+)NCBINCBI36Build 36hg18NCBI36
Build 3494,975,244 - 5,117,995NCBI
Celera94,910,860 - 5,053,802 (+)NCBICelera
Cytogenetic Map9p24.1NCBI
HuRef94,940,783 - 5,083,727 (+)NCBIHuRef
CHM1_194,985,470 - 5,128,355 (+)NCBICHM1_1
T2T-CHM13v2.094,989,498 - 5,135,022 (+)NCBIT2T-CHM13v2.0
Jak2
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391929,229,006 - 29,290,495 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1929,229,228 - 29,290,480 (+)EnsemblGRCm39 Ensembl
GRCm381929,251,803 - 29,313,095 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1929,251,828 - 29,313,080 (+)EnsemblGRCm38mm10GRCm38
MGSCv371929,326,318 - 29,387,570 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361929,318,452 - 29,377,979 (+)NCBIMGSCv36mm8
Celera1930,028,576 - 30,089,642 (+)NCBICelera
Cytogenetic Map19C1NCBI
cM Map1923.73NCBI
Jak2
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049554349,227,595 - 9,341,208 (+)EnsemblChiLan1.0
ChiLan1.0NW_0049554349,227,897 - 9,341,208 (+)NCBIChiLan1.0ChiLan1.0
JAK2
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v211119,420,003 - 119,589,890 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan19119,425,950 - 119,595,837 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v094,820,303 - 4,971,867 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.195,006,271 - 5,156,626 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl95,006,271 - 5,156,626 (+)Ensemblpanpan1.1panPan2
JAK2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1193,321,055 - 93,438,898 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl193,142,635 - 93,435,997 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha193,730,062 - 93,844,204 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0193,940,875 - 93,989,640 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl193,877,224 - 93,990,814 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1193,507,891 - 93,622,032 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0193,232,417 - 93,346,624 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0193,996,654 - 94,110,963 (+)NCBIUU_Cfam_GSD_1.0
Jak2
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024404947140,931,052 - 141,061,286 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936503110,963 - 241,867 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_004936503111,722 - 243,627 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
JAK2
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1216,848,689 - 217,002,148 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11216,849,744 - 217,002,310 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21242,696,921 - 242,837,407 (-)NCBISscrofa10.2Sscrofa10.2susScr3
JAK2
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.11274,421,243 - 74,566,766 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1274,421,016 - 74,566,710 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366603862,818,134 - 62,927,470 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Jak2
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247369,724,369 - 9,830,365 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247369,724,876 - 9,827,364 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Jak2
220 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:118
Count of miRNA genes:88
Interacting mature miRNAs:101
Transcripts:ENSRNOT00000021217
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1150700247252085048Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512256448636Rat
1357335Bw39Body weight QTL 393.3body mass (VT:0001259)body weight (CMO:0000012)1197814409242814409Rat
2302375Bw83Body weight QTL 834.870.0002body mass (VT:0001259)body weight (CMO:0000012)1197697768242697768Rat
1354652Kidm20Kidney mass QTL 204.3kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1177227632256448636Rat
2293674Bss39Bone structure and strength QTL 397.10.0001femur strength trait (VT:0010010)femur total energy absorbed before break (CMO:0001677)1201554356246554356Rat
2302378Insul11Insulin level QTL 113.25blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1144267353251128347Rat
61455Niddm7Non-insulin dependent diabetes mellitus QTL 75.5blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1214537555238757011Rat
61327Eae7Experimental allergic encephalomyelitis QTL 75.6body mass (VT:0001259)change in body weight (CMO:0002045)1216255568260522016Rat
1600392Bw123Body weight QTL 1230.001body mass (VT:0001259)body weight (CMO:0000012)1223201027260522016Rat
7794788Mcs32Mammary carcinoma susceptibility QTL 322.61mammary gland integrity trait (VT:0010552)mammary tumor incidence/prevalence measurement (CMO:0000946)1115540693238914717Rat
1578763Kidm29Kidney mass QTL 293.30.0001kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1179567751260522016Rat
1600395Niddm69Non-insulin dependent diabetes mellitus QTL 694.140.0002blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1195804352257091168Rat
1354624Cm35Cardiac mass QTL355.7heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1177227632256448636Rat
1600396Niddm68Non-insulin dependent diabetes mellitus QTL 684.970.0003blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
1600397Edcs4Endometrial carcinoma susceptibility QTL 42.2uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)1206081677251081677Rat
631838Niddm36Non-insulin dependent diabetes mellitus QTL 360.01insulin secretion trait (VT:0003564)calculated pancreatic islet insulin release measurement (CMO:0001217)1184550676229550676Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1153136852260522016Rat
1600388Niddm67Non-insulin dependent diabetes mellitus QTL 675.840.000004blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
2293694Bss38Bone structure and strength QTL 387.050.0001femur strength trait (VT:0010010)femur stiffness (CMO:0001674)1201554356246554356Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1150700247252085048Rat
8655655Arrd2Age-related retinal degeneration QTL 27.79retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1183970203243914901Rat
734767Niddm57Non-insulin dependent diabetes mellitus QTL 57body mass (VT:0001259)body weight (CMO:0000012)1224054293260122809Rat
1358898Bp255Blood pressure QTL 2553.6arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1191019702246062233Rat
631215Stl8Serum triglyceride level QTL 89.270.0001blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)1225126575260522016Rat
631843Bw116Body weight QTL 1164.10.016abdominal adipose amount (VT:1000220)abdominal fat pad weight (CMO:0000088)1224054293260122809Rat
2300175Bmd40Bone mineral density QTL 4015.40.0001femur mineral mass (VT:0010011)bone mineral density (CMO:0001226)1201554356246554356Rat
731175Uae20Urinary albumin excretion QTL 203.50.0018urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1221264111259647894Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
724538Kidm1Kidney mass QTL 13.2kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1213707201252085212Rat
2293655Bss36Bone structure and strength QTL 3610.660.0001femur strength trait (VT:0010010)femur ultimate force (CMO:0001675)1201554356246554356Rat
1298084Thym4Thymus enlargement QTL 410.68thymus mass (VT:0004954)thymus weight to body weight ratio (CMO:0000612)1197814409242814409Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1150700142252085212Rat
8552891Epfw5Epididymal fat weight QTL 54.4epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1193113876238113876Rat
734769Niddm58Non-insulin dependent diabetes mellitus QTL 58body mass (VT:0001259)body weight (CMO:0000012)1224569538260122809Rat
734768Niddm59Non-insulin dependent diabetes mellitus QTL 59body mass (VT:0001259)body weight (CMO:0000012)1213843987258843987Rat
1358890Bp259Blood pressure QTL 2593.06arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1210702053260522016Rat
724533Rf51Renal function QTL 515.30.0002kidney plasma flow trait (VT:0005524)renal plasma flow (CMO:0001914)1218753816256448513Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1156677124256448636Rat
1358292Cm37Cardiac mass QTL 376.28e-07heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)1196248093241248093Rat
61376Bp42Blood pressure QTL 4223.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1197814409242814409Rat
634313Niddm43Non-insulin dependent diabetes mellitus QTL 43blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1199050459259647894Rat
1549910Bw54Body weight QTL 540.05body mass (VT:0001259)body weight (CMO:0000012)1214647894259647894Rat
70211Niddm24Non-insulin dependent diabetes mellitus QTL 243.79blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1214647894259647894Rat
1357399Bw45Body weight QTL 453.05body mass (VT:0001259)body mass index (BMI) (CMO:0000105)1206329708251329708Rat
724552Glom2Glomerulus QTL 23.30.0001kidney glomerulus morphology trait (VT:0005325)count of superficial glomeruli directly contacting the kidney surface (CMO:0001001)1222363780260522016Rat
1357404Bw42Body weight QTL 424.490.0001body mass (VT:0001259)body weight (CMO:0000012)1206329708251329708Rat
10053715Scort24Serum corticosterone level QTL 242.130.0088blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)1221414816260522016Rat
7421630Bp362Blood pressure QTL 3620.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1118608292241799120Rat
1358916Kidm22Kidney mass QTL 223.32kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1210702053240947965Rat
2312564Glom18Glomerulus QTL 182.40.003kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)1185356336231689108Rat
634321Hc1Hypercalciuria QTL 12.91urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1178810256240830002Rat
61400Niddm1Non-insulin dependent diabetes mellitus QTL 111blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1218753689245907899Rat
10059587Bw173Body weight QTL 1733.230.025body mass (VT:0001259)body weight (CMO:0000012)1202069611247069611Rat
2292216Bw80Body weight QTL 803.230.0019body mass (VT:0001259)body weight (CMO:0000012)1213533809243914901Rat
1300168Bp170Blood pressure QTL 1702.76arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1207702246228581766Rat
2292220Bp306Blood pressure QTL 3063.470.00087arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393243914901Rat
10059590Kidm44Kidney mass QTL 443.420.025kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1191033875236033875Rat
1641926Teswt2Testicular weight QTL 22.82testis mass (VT:1000644)both testes wet weight (CMO:0000175)1197697768238755659Rat
631658Cm7Cardiac mass QTL 75.320.0001aorta mass (VT:0002845)aorta weight (CMO:0000076)1196248093241248093Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
2293700Bmd27Bone mineral density QTL 276.60.0001femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)1224054293243747962Rat
2293701Bmd34Bone mineral density QTL 348.30.0001femur strength trait (VT:0010010)femoral neck ultimate force (CMO:0001703)1224054293243747962Rat
8655855Arrd3Age-related retinal degeneration QTL 33.07lens clarity trait (VT:0001304)cataract incidence/prevalence measurement (CMO:0001585)1183970203243914901Rat
1600374Mcs17Mammary carcinoma susceptibility QTL 173mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1197670404242670404Rat
6480786Bw97Body weight QTL 975.03body mass (VT:0001259)body weight (CMO:0000012)1225126575227604520Rat
1600363Hc6Hypercalciuria QTL 62.7urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1203995416244113296Rat
738032Hcas5Hepatocarcinoma susceptibility QTL 53.12liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1176426412257976495Rat
1358191Ept10Estrogen-induced pituitary tumorigenesis QTL 103.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)1192825253243914732Rat
2302040Pia35Pristane induced arthritis QTL 353.80.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)1216255568260522016Rat
7394701Uae46Urinary albumin excretion QTL 463.60.0056urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1201554356246554356Rat
1598821Rf55Renal function QTL 556.3renal blood flow trait (VT:2000006)ratio of change in renal blood flow to change in renal perfusion pressure (CMO:0001239)1218748008257976495Rat

Markers in Region
D1Bda61  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21227,053,939 - 227,054,173 (+)MAPPERmRatBN7.2
Rnor_6.01247,457,272 - 247,457,505NCBIRnor6.0
Rnor_5.01254,705,185 - 254,705,418UniSTSRnor5.0
RGSC_v3.41232,974,514 - 232,974,747UniSTSRGSC3.4
Celera1224,205,855 - 224,206,088UniSTS
Cytogenetic Map1q51-q53UniSTS
RH141418  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21227,054,207 - 227,054,407 (+)MAPPERmRatBN7.2
Rnor_6.01247,457,540 - 247,457,739NCBIRnor6.0
Rnor_5.01254,705,453 - 254,705,652UniSTSRnor5.0
RGSC_v3.41232,974,782 - 232,974,981UniSTSRGSC3.4
Celera1224,206,123 - 224,206,322UniSTS
Cytogenetic Map1q51-q53UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 3 31 45 29 19 29 6 6 74 33 36 11 6
Low 12 12 12 12 2 5 2 5 2
Below cutoff

Sequence


Ensembl Acc Id: ENSRNOT00000087011   ⟹   ENSRNOP00000071877
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1226,995,334 - 227,054,189 (+)Ensembl
Rnor_6.0 Ensembl1247,398,598 - 247,458,509 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000103558   ⟹   ENSRNOP00000081122
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1227,021,067 - 227,054,189 (+)Ensembl
RefSeq Acc Id: NM_031514   ⟹   NP_113702
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81236,408,905 - 236,467,759 (+)NCBI
mRatBN7.21226,995,334 - 227,054,189 (+)NCBI
Rnor_6.01247,398,667 - 247,457,521 (+)NCBI
Rnor_5.01254,646,160 - 254,706,478 (+)NCBI
RGSC_v3.41232,915,995 - 232,974,763 (+)RGD
Celera1224,147,256 - 224,206,104 (+)RGD
Sequence:
RefSeq Acc Id: XM_039097313   ⟹   XP_038953241
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81236,443,747 - 236,468,769 (+)NCBI
mRatBN7.21227,030,176 - 227,054,381 (+)NCBI
RefSeq Acc Id: NP_113702   ⟸   NM_031514
- UniProtKB: Q62689 (UniProtKB/Swiss-Prot),   A6I0V5 (UniProtKB/TrEMBL),   A0A8I5ZSC0 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000071877   ⟸   ENSRNOT00000087011
RefSeq Acc Id: XP_038953241   ⟸   XM_039097313
- Peptide Label: isoform X1
Ensembl Acc Id: ENSRNOP00000081122   ⟸   ENSRNOT00000103558
Protein Domains
FERM   FERM F1 lobe ubiquitin-like   Protein kinase   SH2

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q62689-F1-model_v2 AlphaFold Q62689 1-1132 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen


Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2939 AgrOrtholog
BioCyc Gene G2FUF-55973 BioCyc
Ensembl Genes ENSRNOG00000059968 Ensembl, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ENSRNOG00055031013 UniProtKB/Swiss-Prot
  ENSRNOG00060030737 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000087011.2 UniProtKB/Swiss-Prot
  ENSRNOT00000103558.1 UniProtKB/TrEMBL
  ENSRNOT00055053783 UniProtKB/Swiss-Prot
  ENSRNOT00060053416 UniProtKB/Swiss-Prot
Gene3D-CATH 2.30.29.30 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  3.30.505.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Transferase(Phosphotransferase) domain 1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Band_41_domain UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FERM_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FERM_central UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FERM_domain UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FERM_F1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FERM_F2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Jak1_PHL_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  JAK2_FERM_C-lobe UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  JAK2_SH2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kinase-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PH-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Prot_kinase_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Protein_kinase_ATP_BS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTK_Jak2_rpt1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTKc_Jak2_rpt2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ser-Thr/Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SH2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SH2_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_AS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_non-rcpt_Jak/Tyk2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_non-rcpt_Jak2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:24514 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
NCBI Gene 24514 ENTREZGENE
PANTHER TYROSINE-PROTEIN KINASE HOPSCOTCH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TYROSINE-PROTEIN KINASE JAK2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam FERM_F1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FERM_F2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Jak1_Phl UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Pkinase_Tyr UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SH2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PharmGKB JAK2 RGD
PhenoGen Jak2 PhenoGen
PIRSF TyrPK_Jak UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PRINTS JANUSKINASE UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  JANUSKINASE2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TYRKINASE UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE FERM_3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PROTEIN_KINASE_ATP UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PROTEIN_KINASE_DOM UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PROTEIN_KINASE_TYR UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SH2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000059968 RatGTEx
  ENSRNOG00055031013 RatGTEx
  ENSRNOG00060030737 RatGTEx
SMART B41 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SH2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TyrKc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP PH domain-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF47031 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF55550 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF56112 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A8I5ZSC0 ENTREZGENE, UniProtKB/TrEMBL
  A6I0V5 ENTREZGENE, UniProtKB/TrEMBL
  A6I0V6_RAT UniProtKB/TrEMBL
  JAK2_RAT UniProtKB/Swiss-Prot
  O35804_RAT UniProtKB/TrEMBL
  Q62689 ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2002-06-10 Jak2  Janus kinase 2 (a protein tyrosine kinase)      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_domains contains two tandem protein kinase related domain 633059
gene_expression mRNA expressed in brain and spleen 633059
gene_homology 93.4% nucleotide and 97.1% amino acid homology with murine Jak2 633059
gene_product member of Janus family; non receptor protein tyrosine kinase 633059